CYP2C8 and cancer: While our analysis using the cancer population model did not suggest alterations in CYP3A4 and CYP2C8 expressions in patients with cancer, it is essential to consider the limited number of drugs evaluated and their ADME properties (e.g., the contribution of CYP3A4 to overall clearance being equal or less than 80%) and cancer type.